Advertisement
News
Advertisement

Corporation Also Announces Grant of Options and Deferred Stock Units

Wed, 02/15/2012 - 2:45am
The Associated Press

(http://www.ventripoint.com/)

VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) has

installed its latest version of the VMS heart analysis system at

ERASMUS MC SOPHIA (Sophia) Children's Hospital in Rotterdam,

Netherlands. Sophia will introduce the VMS system into routine

clinical use for Tetrology of Fallot (Blue Baby Syndrome) or Systemic

Right Ventricle patients, under the supervision of Dr. Willem Helbing

and Dr. Laurens Koopman.

"The VentriPoint system combines the best of both worlds: the ease and

availability of 2D echo and the intrinsic 3D information of the MRI

acquired shapes of the right ventricle in the database. We anticipate

a reduction of the need for (expensive) cardiac Magnetic Resonance

Imaging (MRI) for the purpose of assessment of right ventricle

volumes", said Dr. Helbing.

Dr. Helbing is the Head of Pediatric Cardiology for Sophia, and has a

history with VentriPoint as he was an early collaborator and provided

valuable insight into the product development. VMS uses Knowledge

Based Reconstruction (KBR) to accurately create the surface volume of

the right ventricle. KBR is based on a library of hearts that are

disease specific. Dr. Helbing provided guidance and MRI heart images

that VentriPoint incorporated into its heart libraries for Tetrology

of Fallot and Systemic Right Ventricle.

"Dr. Helbing was one of the first people I called when I joined

VentriPoint," said Dr. George Adams, CEO of VentriPoint. "It is

wonderful we can now supply him with the newest version of the VMS

which meets his clinical needs."

Approximately, 0.8% of the live births in the Netherlands are born

with some form of congenital heart disease. The more severe cases

require life-long monitoring of their right ventricle.

The Corporation also announces that it has granted 2,550,000 options

to certain officers of the Corporation. The options are exercisable at

$0.17 per share until the fifth anniversary date of the grant. In

addition, the Corporation announces that it has granted a total of

450,000 Deferred Stock Units (DSU) to certain directors. Under the

terms of the Corporation's Deferred Share Unit Plan, holders of DSU

may redeem each DSU for one share of Common Stock upon the termination

of their services to the Corporation at no cost to the holder.

About Dr. Willem Helbing

Dr. Helbing has combined a clinical career as paediatric cardiologist

with a research interest in ventricular function in congenital heart

disease. He has used various models and techniques, particularly MRI,

to study right and single ventricular function in children and young

adults with congenital heart disease. He currently is a professor in

paediatrics and Head of Paediatric Cardiology at Erasmus University

Medical Center and Sophia Children Hospital.

About Erasmus MC

Erasmus MC is the largest and most versatile of the eight university

medical centers in the Netherlands. Erasmus MC wants to further extend

its international reputation and become one of the twenty best medical

institutes in the world by 2013. The organization consists of over

fifty departments. Each department contributes to Erasmus MC's three

core tasks: patient care; research; and education.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor

patients with heart disease, a leading cause of death in developed

countries. Management believes the VMS is the first cost-effective

and accurate diagnostic tool for measuring right ventricle heart

function. Congenital heart disease is the first application in a suite

of applications for all major heart diseases including pulmonary

hypertension, cardiovascular disease and heart failure, which

management believes has a multibillion-dollar market potential. Canada

and Europe (CE Mark) have granted approval for the sale of

VentriPoint's VMS heart analysis system and VentriPoint is pursuing

the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release

that are not historical facts contain forward-looking information that

involves risk and uncertainties. All statements, other than statements

of historical facts, which address VentriPoint's expectations, should

be considered forward-looking statements. Such statements are based on

management's exercise of business judgment as well as assumptions made

by and information currently available to management. When used in

this document, the words "may", "will", "anticipate", "believe",

"estimate", "expect", "intend" and words of similar import, are

intended to identify any forward-looking statements. You should not

place undue reliance on these forward-looking statements. These

statements reflect a current view of future events and are subject to

certain risks and uncertainties as contained in the Corporation's

filings with Canadian securities regulatory authorities. Should one or

more of these risks or uncertainties materialize, or should underlying

assumptions prove incorrect, actual results could differ materially

from those anticipated in these forward-looking statements. These

forward-looking statements are made as of the date of this press

release and, other than as required by applicable securities laws, the

Corporation does not assume any obligation to update or revise them to

reflect new events or circumstances. Although management believes that

expectations are based on reasonable assumptions, no assurance can be

given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading